John Silberholz

By |

Most of my research related to data science involves decision making around clinical trials. In particular, I am interested in how databases of past clinical trial results can inform future trial design and other decisions. Some of my work has involved using machine learning and mathematical optimization to design new combination therapies for cancer based on the results of past trials. Other work has used network meta-analysis to combine the results of randomized controlled trials (RCTs) to better summarize what is currently known about a disease, to design further trials that would be maximally informative, and to study the quality of the control arms used in Phase III trials (which are used for drug approvals). Other work combines toxicity data from clinical trials with toxicity data from other data sources (claims data and adverse event reporting databases) to accelerate detection of adverse drug reactions to newly approved drugs. Lastly, some of my work uses Bayesian inference to accelerate clinical trials with multiple endpoints, learning the link between different endpoints using past clinical trial results.